HiberCell, Inc. has acquired the Imprime PGG program from Biothera Pharmaceuticals, Inc.
This website will deactivate on August 31. To learn more visit HiberCell.com

Monthly Archives: June 2019

Biothera Pharmaceuticals Presents Clinical Data from Phase 2 Study Evaluating the Combination of Imprime PGG and Merck’s KEYTRUDA in Triple Negative Breast Cancer at 2019 ASCO Annual Meeting

Imprime PGG is a dectin receptor agonist that triggers anti-cancer immune responses IMPRIME 1 study enrolled 44 previously treated, metastatic triple negative breast cancer (TNBC) patients 15.9% Overall Response Rate (Three previous TNBC clinical studies with checkpoint inhibitor (CPI) monotherapies generated response rates of 5% to 6%) 25% Disease Control Rate >24 weeks 13.7 months median Overall Survival, with 64.2% patient survival at 12 months...

Read More